biostudies-literatureKumar SNCI NIH HHS39https://www.ebi.ac.uk/biostudies/studies/S-EPMC6281679biostudies-literatureUnknown4Serial monitoring of plasma DNA mutations in estrogen receptor positive metastatic breast cancer (ER + MBC) holds promise as an early predictor of therapeutic response. Here, we developed dPCR-SEQ, a customized assay that utilizes digital PCR-based target enrichment followed by next-generation sequencing to analyze plasma DNA mutations in <i>ESR1</i>, <i>PIK3CA</i>, and <i>TP53</i>. We validated dPCR-SEQ in a prospective cohort of 58 patients with ER + MBC and demonstrate excellent concordance with hotspot <i>ESR1</i> mutation abundance measured by conventional digital PCR. The dPCR-SEQ assay revealed <i>ESR1</i>, <i>PIK3CA</i>, and <i>TP53</i> plasma ctDNA mutations in 55%, 32%, and 32% of the study patients, respectively. We also observed dynamic changes in <i>ESR1</i>, <i>PIK3CA</i>, and <i>TP53</i> ctDNA mutant allele fraction (MAF) that were frequently discordant between the different genes. Thus, monitoring plasma DNA mutation dynamics using a dPCR-SEQ assay is feasible, accurate, and may be investigated as a biomarker of therapeutic response in ER + MBC.NPJ breast cancerTracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer with dPCR-SEQ.PMC6281679P50 CA058223Gupta GPTan XMCarey LAChen QBGarrett ALLindsay DAnders CKKumar SfalseTracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer with dPCR-SEQ.Serial monitoring of plasma DNA mutations in estrogen receptor positive metastatic breast cancer (ER + MBC) holds promise as an early predictor of therapeutic response. Here, we developed dPCR-SEQ, a customized assay that utilizes digital PCR-based target enrichment followed by next-generation sequencing to analyze plasma DNA mutations in <i>ESR1</i>, <i>PIK3CA</i>, and <i>TP53</i>. We validated dPCR-SEQ in a prospective cohort of 58 patients with ER + MBC and demonstrate excellent concordance with hotspot <i>ESR1</i> mutation abundance measured by conventional digital PCR. The dPCR-SEQ assay revealed <i>ESR1</i>, <i>PIK3CA</i>, and <i>TP53</i> plasma ctDNA mutations in 55%, 32%, and 32% of the study patients, respectively. We also observed dynamic changes in <i>ESR1</i>, <i>PIK3CA</i>, and <i>TP53</i> ctDNA mutant allele fraction (MAF) that were frequently discordant between the different genes. Thus, monitoring plasma DNA mutation dynamics using a dPCR-SEQ assay is feasible, accurate, and may be investigated as a biomarker of therapeutic response in ER + MBC.2018-01-01T00:00:00Z20182024-11-20T05:21:08.819Z2019-03-27T00:11:45ZS-EPMC62816793053459610.1038/s41523-018-0093-3